Search clinical trials for: Филовирусы

Total 10 results

Janssen Vaccines & Prevention B.V.
Bavarian Nordic GmbH

Terminated

Long-term Safety Follow-up of Participants Exposed to the Candidate Ebola Vaccines Ad26.ZEBOV and/or MVA-BN-Filo

Hemorrhagic Fever, Ebola

France, United Kingdom, Kenya, United States, Uganda, Burkina Faso, Tanzania
Janssen Vaccines & Prevention B.V.

Completed

A Study to Evaluate A Range of Dose Levels of Ad26.ZEBOV and MVA-BN-Filo in Healthy Adult Participants

Healthy

United States
Crucell Holland BV

Completed

A Study to Evaluate the Immunogenicity, Safety and Tolerability of Ad26.ZEBOV and MVA-BN-Filo in Healthy Adult Participants

Healthy

United States
Janssen Vaccines & Prevention B.V.
Institut National de la Santé Et de la Recherche Médicale, France; Centre Muraz and other collaborators

Completed

Safety, Tolerability and Immunogenicity Study of 3 Prime-boost Regimens for Ebola Vaccines Ad26.ZEBOV/MVA-BN-Filo in Healthy Adults, Children and Human Immunodeficiency Virus Positive (HIV+) Adults

Hemorrhagic Fever, Ebola

Kenya, Uganda, Burkina Faso, Côte D'Ivoire
Janssen Vaccines & Prevention B.V.
Walter Reed Army Institute of Research (WRAIR)

Completed

Safety, Tolerability and Immunogenicity Study of 2-dose Heterologous Regimens for Ebola Vaccines Ad26.ZEBOV/MVA-BN-Filo

Hemorrhagic Fever, Ebola

United States, Uganda, Kenya, Mozambique, Nigeria, Tanzania
Janssen Vaccines & Prevention B.V.
Institut National de la Santé Et de la Recherche Médicale, France; University...

Completed

A Study to Assess Safety, Tolerability, and Immunogenicity of Three Heterologus 2-dose Regimens of the Candidate Prophylactic Vaccines for Ebola in Healthy Adults

Ebola Viral Disease

France, United Kingdom
Janssen Vaccines & Prevention B.V.

Completed

A Safety and Immunogenicity Study of Heterologous and Homologous Prime-Boost Ebola Vaccine Regimens in Healthy Participants

Healthy

United States
Crucell Holland BV

Completed

A Safety and Immunogenicity Study of Heterologous Prime-Boost Ebola Vaccine Regimens in Healthy Participants

Healthy

United Kingdom
Crucell Holland BV

Completed

A Study to Evaluate the Safety and Immunogenicity of Heterologous Prime-Boost Ebola Vaccine Regimens in Healthy Participants

Healthy

Kenya
Crucell Holland BV

Completed

A Study to Assess the Safety and Immunogenicity of Heterologous Prime-Boost Ebola Vaccine Regimens in Healthy Participants

Healthy

Tanzania, Uganda

3

Subscribe